aTYR PHARMA INC financial data

Symbol
ATYR on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
10240 Sorrento Valley Road, Suite 300, San Diego, California
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 696 % -11%
Return On Equity -65.4 % -32%
Return On Assets -49.8 % -27.6%
Operating Margin -10.6K %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 75.8M shares +32.9%
Common Stock, Shares, Outstanding 75.8M shares +32.9%
Entity Public Float 121M USD +56.5%
Common Stock, Value, Issued 76K USD +33.3%
Weighted Average Number of Shares Outstanding, Basic 72.3M shares +31.1%
Weighted Average Number of Shares Outstanding, Diluted 72.3M shares +31.1%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 588K USD
Research and Development Expense 50.4M USD +14.6%
General and Administrative Expense 12.7M USD -10.4%
Operating Income (Loss) -62.5M USD -30.8%
Nonoperating Income (Expense) 4.63M USD +69.9%
Net Income (Loss) Attributable to Parent -57.9M USD -28.5%
Earnings Per Share, Basic -0.89 USD/shares +27.6%
Earnings Per Share, Diluted -0.89 USD/shares +27.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 6.81M USD -44.7%
Assets, Current 90.3M USD -21.1%
Property, Plant and Equipment, Net 5.18M USD -10.8%
Operating Lease, Right-of-Use Asset 5.94M USD -16.5%
Other Assets, Noncurrent 130K USD +80.6%
Assets 106M USD -20.2%
Accounts Payable, Current 1.26M USD +143%
Employee-related Liabilities, Current 2.71M USD -2.7%
Accrued Liabilities, Current 9.41M USD -12.8%
Liabilities, Current 11.8M USD -4.29%
Operating Lease, Liability, Noncurrent 11.5M USD -10.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax -168K USD +49.6%
Retained Earnings (Accumulated Deficit) -500M USD -13.1%
Stockholders' Equity Attributable to Parent 81.6M USD -23.2%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 81.4M USD -23.2%
Liabilities and Equity 106M USD -20.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -22.4M USD -3693%
Net Cash Provided by (Used in) Financing Activities 7.73M USD -84.4%
Net Cash Provided by (Used in) Investing Activities -1.36M USD +96.4%
Common Stock, Shares Authorized 170M shares 0%
Common Stock, Shares, Issued 75.8M shares +32.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -16M USD -249%
Interest Paid, Excluding Capitalized Interest, Operating Activities 38K USD -17.4%
Deferred Tax Assets, Valuation Allowance 108M USD +13.1%
Deferred Tax Assets, Gross 109M USD +12.8%
Operating Lease, Liability 12.2M USD -13.5%
Payments to Acquire Property, Plant, and Equipment 17K USD -98.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -57.7M USD -29.5%
Property, Plant and Equipment, Gross 10.2M USD +7.85%
Operating Lease, Liability, Current 656K USD +5.64%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.78M USD -9.87%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.72M USD -10.1%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 5.9M USD -7.75%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.92M USD -0.36%
Deferred Tax Assets, Operating Loss Carryforwards 60.1M USD +13.9%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 30.1M USD +19.6%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.94M USD +9.29%
Additional Paid in Capital 582M USD +6.03%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 178K USD +123%
Deferred Tax Assets, Net of Valuation Allowance 1.41M USD -7.22%
Share-based Payment Arrangement, Expense 2.79M USD +11.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%